SEGMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2021

Segment Profitability and Segment Assets

The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below:


	Three Months Ended				Six Months Ended
	April 30,				April 30,
	2021		2020		2021		2020
	(in millions)
Net Revenue:
Life Sciences and Applied Markets	$	674	$	526	$	1,396	$	1,164
Diagnostics and Genomics	315		263		609		512
Agilent CrossLab	536		449		1,068		919
Total net revenue	$	1,525	$	1,238	$	3,073	$	2,595

Segment Income From Operations:
Life Sciences and Applied Markets	$	154	$	98	$	353	$	256
Diagnostics and Genomics	69		57		124		91
Agilent CrossLab	141		122		283		241
Total segment income from operations	$	364	$	277	$	760	$	588

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.


	April 30, 2021		October 31, 2020
	(in millions)
Segment Assets:
Life Sciences and Applied Markets	$	3,119	$	3,143
Diagnostics and Genomics	3,262		2,515
Agilent CrossLab	1,425		1,375
Total segment assets	$	7,806	$	7,033

Reconciliation of segment results to total enterprise results

The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes:


	Three Months Ended				Six Months Ended
	April 30,				April 30,
	2021		2020		2021		2020
	(in millions)
Total segment income from operations	$	364	$	277	$	760	$	588
Transformational initiatives	(9)		(15)		(20)		(28)
Amortization of intangible assets related to business combinations	(46)		(46)		(90)		(94)
Acquisition and integration costs	(13)		(11)		(22)		(24)
Asset impairment	(2)		(99)		(2)		(99)

Business exit and divestiture costs	(3)		—		(4)		—



Other(1)	(3)		(4)		(6)		(26)
Interest income	1		3		1		6
Interest expense	(20)		(20)		(39)		(40)
Other income (expense), net (2)	4		36		7		57
Income before taxes, as reported	$	273	$	121	$	585	$	340

(1) For the six months ended April 30, 2020, the other category primarily includes the legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments.

(2) For the three and six months ended April 30, 2020 other income (expense), net includes the settlement of the legal claim against Twist Bioscience Corporation.